Abstract:Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the largest pandemic for more than a year, leading to more than 200 million infections and contributing to massive losses of human lives and economic productivities worldwide. Recent development with the delta variant further complicated the control of this pandemic. In addition to acute illness in severe cases, long-term sequelae caused by COVID-19 are emerging,1Marshall M. The four most urgent questions about long COVID.Nature. 2021; 594: 168-170Crossref PubMed Scopus (37) Google Scholar including pulmonary fibrosis and possibly persistent immune-related disorders.2Wang E.Y. Mao T. Klein J. et al.Diverse functional autoantibodies in patients with COVID-19.Nature. 2021; 595: 283-288Crossref PubMed Scopus (341) Google Scholar From clinical and pathologic observations, it is evident that the virus can cause systematic infection and functional abnormalities in multiple systems to various degrees.3Tian S. Xiong Y. Liu H. et al.Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.Mod Pathol. 2020; 33: 1007-1014Crossref PubMed Scopus (599) Google Scholar,4Polak S.B. Van Gool I.C. Cohen D. von der Thüsen J.H. van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.Mod Pathol. 2020; 33: 2128-2138Crossref PubMed Scopus (273) Google Scholar Nevertheless, the upper and lower respiratory tracts remain the main target of infection by SARS-CoV-2, and viral pneumonitis is the predominant manifestation and cause of mortality in most of the severely ill patients.5Tian S. Hu W. Niu L. Liu H. Xu H. Xiao S.Y. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer.J Thorac Oncol. 2020; 15: 700-704Abstract Full Text Full Text PDF PubMed Scopus (965) Google Scholar,6Ackermann M. Verleden S.E. Kuehnel M. et al.Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19.N Engl J Med. 2020; 383: 120-128Crossref PubMed Scopus (3364) Google Scholar Clinically, symptomatic COVID-19 may be roughly divided to three stages4Polak S.B. Van Gool I.C. Cohen D. von der Thüsen J.H. van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.Mod Pathol. 2020; 33: 2128-2138Crossref PubMed Scopus (273) Google Scholar based on the manifestations. The earliest stage is characterized by influenza-like symptoms. In the second stage, patients can develop viral pneumonia with pulmonary inflammation and coagulation dysfunctions, with elevated inflammatory biomarkers. The final stage of COVID-19 can be characterized by fibrosis.4Polak S.B. Van Gool I.C. Cohen D. von der Thüsen J.H. van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.Mod Pathol. 2020; 33: 2128-2138Crossref PubMed Scopus (273) Google Scholar These three stages can occur consecutively or simultaneously. Since our first descriptions of lung pathology in patients with early COVID-19 and fatal cases, there have been many autopsy-based studies,4Polak S.B. Van Gool I.C. Cohen D. von der Thüsen J.H. van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.Mod Pathol. 2020; 33: 2128-2138Crossref PubMed Scopus (273) Google Scholar,7Caramaschi S. Kapp M.E. Miller S.E. et al.Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review.Mod Pathol. 2021; 34: 1614-1633Crossref Scopus (56) Google Scholar yielding a spectrum or patterns of histopathology of the lungs. The acute changes range from epithelial injury and loss, diffuse alveolar damages (DADs), to subsequent infiltration by mixed inflammatory cellular infiltration, including activated macrophages5Tian S. Hu W. Niu L. Liu H. Xu H. Xiao S.Y. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer.J Thorac Oncol. 2020; 15: 700-704Abstract Full Text Full Text PDF PubMed Scopus (965) Google Scholar,7Caramaschi S. Kapp M.E. Miller S.E. et al.Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review.Mod Pathol. 2021; 34: 1614-1633Crossref Scopus (56) Google Scholar with associated inflammatory cytokine release. Some authors described these as the following patterns4Polak S.B. Van Gool I.C. Cohen D. von der Thüsen J.H. van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.Mod Pathol. 2020; 33: 2128-2138Crossref PubMed Scopus (273) Google Scholar: the epithelial pattern of lung injury is the most common change, characterized by DAD with hyaline membrane formation, whereas the vascular pattern of lung injury features microthrombi and proteinaceous and fibrinous exudates, and the fibrotic pattern is typified by interstitial fibrosis. It is believed that all these were initiated by attachment of SARS-CoV-2 to host cells through the binding of its spike (S) glycoprotein and the ACE2, followed by the cleavage of ACE2 by the TMPRSS2, allowing for viral entry.8Lukassen S. Chua R.L. Trefzer T. et al.SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.EMBO J. 2020; 39e105114Crossref PubMed Scopus (638) Google Scholar Despite its critical role in the initiation of viral infection, studies have revealed that ACE2 is expressed at very low levels in the lungs.9Wang S. Qiu Z. Hou Y. et al.AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.Cell Res. 2021; 31: 126-140Crossref PubMed Scopus (245) Google Scholar Evidently, there need to be other host receptors or mechanisms that promote the entry of SARS-CoV-2 into respiratory cells and tissue injury. In this issue of the Journal of Thoracic Oncology, by performing bioinformatics analysis of several public domain data sets, Stewart et al.10Stewart C.A. Gay C.M. Ramkumar K. et al.Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.J Thorac Oncol. 2021; 16: 1821-1839Abstract Full Text Full Text PDF Scopus (18) Google Scholar evaluated the expression and regulation of ACE2 and TMPRSS2 in a variety of cell lines, tumor biopsy specimens, and data from cancer cell lines and bronchial organoids infected by SARS-CoV-2 and patient nasal epithelium. Single-cell transcriptional group level revealed that ACE2 is expressed in only a small number of cells in normal respiratory tract, and the expression of TMPRSS2 is more extensive than that of ACE2 in fibrotic lung tissue. In contrast, the authors found that ACE2 was highly expressed in NSCLC cell lines and The Cancer Genome Atlas tumors. Consistently, the data from 180 patients with lung cancer and COVID-19 from eight countries revealed that the mortality rate of patients with lung cancer infected with COVID-19 is higher than that of the general population.11Garassino M.C. Whisenant J.G. Huang L.C. et al.COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.Lancet Oncol. 2020; 21: 914-922Abstract Full Text Full Text PDF PubMed Scopus (408) Google Scholar Interestingly, our unpublished data revealed that ACE2 expression is extremely low in normal lung tissues adjacent to lung cancer, and in lung tissues of other diseases including hamartoma, alveolar cell tumor, and infectious diseases. Previous studies had revealed that the expression of ACE2 can be down-regulated by SARS-CoV-1 infection, making the lung tissue more susceptible to acute injury, and less likely reinfection in the same tissue,12Imai Y. Kuba K. Rao S. et al.Angiotensin-converting enzyme 2 protects from severe acute lung failure.Nature. 2005; 436: 112-116Crossref PubMed Scopus (1876) Google Scholar suggesting subsequent tissue injuries and lung diseases are secondary "downstream" events in the pathogenesis. These point to the possibility of another mechanism of COVID-19 pathology, which may involve epithelia-mesenchymal interactions or transformations (epithelial-to-mesenchymal transition [EMT]), facilitating the compromise of the epithelial barrier. As revealed in the study by Stewart et al.,10Stewart C.A. Gay C.M. Ramkumar K. et al.Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.J Thorac Oncol. 2021; 16: 1821-1839Abstract Full Text Full Text PDF Scopus (18) Google Scholar long-term exposure to SARS-CoV-2 up-regulated the expression of mesenchymal genes in human bronchial epithelial cells, including AXL, but down-regulated the expression of tight junction-related genes, suggesting cells infected with SARS-CoV-2 can undergo metabolic and transcriptional changes consistent with EMT. Destruction of tight junctions between cells can directly lead to damage of the alveolar epithelial barrier. The resultant pathologic changes of alveolar edema and proteinaceous exudation were consistent with the main pathologic changes of the lungs in patients with COVID-19,3Tian S. Xiong Y. Liu H. et al.Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.Mod Pathol. 2020; 33: 1007-1014Crossref PubMed Scopus (599) Google Scholar which were DAD and interstitial dimension.3Tian S. Xiong Y. Liu H. et al.Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.Mod Pathol. 2020; 33: 1007-1014Crossref PubMed Scopus (599) Google Scholar Considering the pathologic findings of pulmonary fibrosis observed in some patients with COVID-19, it may be reasonable to assume that EMT in COVID-19 could be consequential. Remarkably, AXL has been identified as a potential receptor for SARS-CoV-2 because AXL knockout can significantly reduce the infection of SARS-CoV-2 in human lung epithelial cells.9Wang S. Qiu Z. Hou Y. et al.AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.Cell Res. 2021; 31: 126-140Crossref PubMed Scopus (245) Google Scholar Notably, their study revealed that bemcentinib, an inhibitor of AXL, could down-regulate the expression of mesenchymal-related gene and up-regulate the expression of ACE2.10Stewart C.A. Gay C.M. Ramkumar K. et al.Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.J Thorac Oncol. 2021; 16: 1821-1839Abstract Full Text Full Text PDF Scopus (18) Google Scholar Postmortem biopsy results in patients with COVID-19 revealed that a subset of pneumocytes is double positive for epithelial and mesenchymal markers, CK7 and α-SMA, respectively, suggesting the establishment of pulmonary fibrosis through the EMT mechanism.13Pandolfi L. Bozzini S. Frangipane V. et al.Neutrophil extracellular traps induce the epithelial-mesenchymal transition: implications in post-COVID-19 fibrosis.Front Immunol. 2021; 12: 663303Crossref Scopus (24) Google Scholar With these findings, it is suggested that EMT plays a vital role in the pathophysiology changes of COVID-19, including the SARS-CoV-2 infection and pulmonary fibrosis. Although the findings in the study by Stewart et al.10Stewart C.A. Gay C.M. Ramkumar K. et al.Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.J Thorac Oncol. 2021; 16: 1821-1839Abstract Full Text Full Text PDF Scopus (18) Google Scholar are intriguing and promising, it is worthwhile to note that these analyses were heavily relied on data from various sources but not prospectively designed and well-controlled experiments. There might be variations owing to difference in data source, "signal" changes associated with passaging of cell lines, difference in types of malignancies, and age of cells. Cancer cell lines are susceptible to additional genetic and phenotypic changes, as compared with nontransformed cells in most patients with COVID-19. That being said, this study provided a valuable concept and basis for future studies focusing on cells with well-defined lineage history, well-defined cytologic phenotypes, and experiments with virus-infected cell cultures. The new model proposed by Stewart et al.10Stewart C.A. Gay C.M. Ramkumar K. et al.Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.J Thorac Oncol. 2021; 16: 1821-1839Abstract Full Text Full Text PDF Scopus (18) Google Scholar seems to support the notion that although ACE2 is important in the initial infection of SARS-CoV-2, the progression and outcome of COVID-19 depend more on other complex host-pathogen interactions, including virulence, replication, and host immune response.14Yang C. Li Y. Xiao S.Y. Differential expression of ACE2 in the respiratory tracts and its relationship to COVID-19 pathogenesis.EBioMedicine. 2020; 60: 103004Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar The observed EMT and reduction of ACE2 may be a previously unrecognized component in the pathophysiology of COVID-19 pneumonitis. Nevertheless, the findings of moderate expression of ACE2 in lungs with tumors, in contrast to healthy lung tissue which has only very low level of ACE2 expression, may be partially responsible for more severe diseases and worse prognosis in patients with lung cancer who suffer from COVID-19. Thus, patients with lung cancer need more effective preventive measures against SARS-CoV-2 infection during the pandemic. The spread of the delta variant of SARS-CoV-2 has made it more urgent to develop and test effective vaccines suitable for patients with lung cancer. Shu-Yuan Xiao: Conceptualization, Original—draft preparation, Writing—review and editing. Yueying Li, Chunxiu Yang: Original—draft preparation, Writing—review and editing. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 PathophysiologyJournal of Thoracic OncologyVol. 16Issue 11PreviewCoronavirus disease 2019 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters host cells through the cell surface proteins ACE2 and TMPRSS2. Full-Text PDF Open Access

Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages

SARS-CoV-2 Infection Triggers Profibrotic Macrophage Responses and Lung Fibrosis

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

Determinants of SARS-CoV-2 Receptor Gene Expression in Upper and Lower Airways

SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues

Single-cell analysis of human lung epithelia reveals concomitant expression of the SARS-CoV-2 receptor ACE2 with multiple virus receptors and scavengers in alveolar type II cells

SARS-CoV2 infection in whole lung primarily targets macrophages that display subset-specific responses

Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?

Comparative analysis of ACE2 protein expression in rodent, non-human primate, and human respiratory tract at baseline and after injury: A conundrum for COVID-19 pathogenesis

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors

COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis

A Molecular Single-Cell Lung Atlas of Lethal COVID-19.

Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus

Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia

Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract

Activation of alveolar epithelial ER stress by β-coronavirus infection disrupts surfactant homeostasis in mice: implications for COVID-19 respiratory failure

A single-cell transcriptomic landscape of the lungs of patients with COVID-19

Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19